论文部分内容阅读
美国ＦＤＡ已批准礼莱公司的抗抑郁药氟西汀(ｆｌｕｏｘｅｔｉｎｅ ,Ｓａｒａｆｅｍ) ,用于月经前焦虑症 (ＰＭＤＤ)的附加指征。氟西汀将于 2 0 0 0年夏季上市。礼莱公司认为 ,启用新品牌名称以避免抑郁症与ＰＭＤＤ相混淆。礼莱公司要求对新产品用不同名字以避免与商品名为Ｐ
The U.S. FDA has approved Lilly’s anti-depressant fluoxetine (Sarafem) for additional indications for premenstrual dysphoric disorder (PMDD). Fluoxetine will be available in the summer of 2000. Lilly Company believes that the new brand name enabled to avoid depression and PMDD confused. Lilly companies require new names for the new product to avoid the trade name P